<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F7145B1B-8E42-46F4-96F1-84C003C73C8C"><gtr:id>F7145B1B-8E42-46F4-96F1-84C003C73C8C</gtr:id><gtr:firstName>Marianne</gtr:firstName><gtr:surname>van der Sande</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190081974"><gtr:id>B5C947E7-F141-4777-9889-F19FD0617BC8</gtr:id><gtr:title>TB or not TB: Randomised controlled trial of tuberculosis treatment before anti-retroviral therapy in HIV patients</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190081974</gtr:grantReference><gtr:abstractText>Patients infected with HIV are more likely to suffer from tuberculosis (TB) disease than non infected individuals. However, TB is often difficult to diagnose, particularly among HIV patients who are sick enough to receive antiretroviral therapy. Because of the presumed high prevalence of TB in these HIV-infected subjects, we postulate that concomitant treatment for TB will substantially improve the clinical outcome. We want to study 100 HIV positive patients who have not yet started anti-retroviral therapy (HAART) and who have not been diagnosed with TB. These patients will receive either a standard TB treatment or placebo. This study will give us the practical value of treating for TB and saving the lives of people with AIDS and provides informed-decision for a translational clinical practice for HIV care.</gtr:abstractText><gtr:technicalSummary>Tuberculosis (TB) is a major cause of morbidity and mortality among HIV-infected patients, especially those with severe immunosuppression (CD4 count below 200 cells/microlitre). However, TB is often difficult to diagnose, in particular among those severely immunosuppressed. This is likely to result in underdiagnosis. There are no guidelines on the management of such patients, which probably leads to many preventable premature deaths. Preliminary culture results of the first patients evaluated as part of another study showed that 11/25 (44%) of those without a clinical or CXR diagnosis of TB were nevertheless infected with mycobacteria.||We hypothesise that empirical treatment for TB will substantially improve clinical outcome in HIV-infected patients with a CD4 count below 200 cells/microlitre, and propose to randomise 100 patients who are not yet started on their induction towards anti-retroviral therapy (HAART) and who have not been diagnosed with TB to either standard TB treatment or placebo. Primary outcome will be clinical improvement after 2 months.</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-06-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>93925</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_U190081974</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>